NCT02679001View on ClinicalTrials.gov

A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 24, 2016

Primary Completion Date

December 7, 2017

Study Completion Date

December 7, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

TNF inhibitor/TCZ

Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.

Trial Locations (11)

18288

Danderyds Sjukhus Ab; Rheumatology, Stockholm

37185

Blekingesjukhuset Karlskrona; Medicin, Rheumatology, Karlskrona

54185

Kaernsjukhuset; Dept of Medicine, Skövde

70185

Örebro Uni Hospital; Rheumatology, Örebro

75185

Akademiska sjukhuset, Reumatologkliniken, Uppsala

671 80

Arvika Sjukhus; Reumatologimottagningen - Medicinmottagningen, Arvika

631 88

Mälarsjukhuset; Reumatologkliniken, Eskilstuna

SE-141 86

Karolinska University Hospital, Huddinge; Rheumatology, Huddinge

205 02

Skånes Universitetssjukhus Malmö; Reumatologkliniken, Malmo

212 28

Capio Citykliniken, Reumatologen, Malmo

231 85

Lasarettet Trelleborg;Reumatologmottagningen, Trelleborg

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02679001 - A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment. | Biotech Hunter | Biotech Hunter